Oslo, Norway (29 March 2021) -

Reference is made to the offer document dated 8 March 2021 (the "Offer Document") for the recommended voluntary offer by Compagnie des Levures Lesaffre (the "Offeror") to acquire all outstanding shares in NattoPharma ASA ("NattoPharma" or the "Company") against a consideration in cash of NOK 35 per share (the "Offer"), and further reference is made to the stock exchange announcement dated 23 March 2021 in which the Offeror announced that the closing conditions "Minimum Acceptance" and "Regulatory Approval" are considered to be fulfilled.

All of the Company's option holders, representing all of the outstanding 1,200,850 options in the Company (the "Company Options"), have irrevocably committed to exercise the Company Options to subscribe for Shares in the Company and to sell such Shares to the Offeror on the same terms and conditions as the Offer.

Based on the authorization granted at the annual general meeting of NattoPharma on June 19, 2020, the Board of Directors of NattoPharma has therefore resolved a share issue of 1,200,850 new shares, each with a nominal value of NOK 3 per share.

The share capital increase has been registered and the Company's new share capital is NOK 63,132,849 divided into 21,044,283 registered shares each with a nominal value of NOK 3.00.

***

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities